- Eli Lilly commits an additional $4.5 billion to two Lebanon manufacturing sites, raising Indiana capital commitments since 2020 to over $21 billion.
- Lilly Lebanon Advanced Therapies, the company's first dedicated genetic medicine manufacturing facility, opened to support clinical and commercial genetic-level modalities.
- Lilly Lebanon API is slated to open in 2027 and will be the largest API production site in U.S. history.
- Planned production at Lebanon includes Foundayo (orforglipron), Zepbound/Mounjaro (tirzepatide) and investigational retatrutide.
Investment
Eli Lilly announced an additional $4.5 billion capital investment across two Lebanon, Indiana manufacturing sites, bringing its Indiana commitments since 2020 to over $21 billion and U.S. commitments since 2020 to more than $50 billion; the increase is driven by an evolving pipeline and anticipated demand for its medicines.
Facilities and capabilities
Lilly Lebanon Advanced Therapies has opened as the company’s first dedicated genetic medicine manufacturing facility, built to support clinical and commercial production across a full spectrum of genetic medicine modalities and requiring new manufacturing processes without established commercial precedent; the Lebanon campus will include three planned sites: Advanced Therapies, Lebanon API and the Lilly Medicine Foundry.
Lebanon API and production
The investment includes new process designs and technologies at Lilly Lebanon API, slated to open in 2027 and described as the largest API production site in U.S. history when complete; planned production at Lebanon includes Zepbound and Mounjaro (tirzepatide), Foundayo (orforglipron) and investigational retatrutide.
Economic impact
A forthcoming Indiana University Kelley School report states Lilly accounts for about 70% of Indiana’s pharmaceutical GDP, that each Lilly job supports more than two additional jobs statewide, and that the company estimates each dollar it spends can generate up to four dollars in additional local economic activity.
